NCT00810953View on ClinicalTrials.gov

A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Pentamidine

two dose of 6 mg/kg with or without standard chemotherapy.

Trial Locations (1)

H2W 1S6

McGill University, Montreal

Sponsors
All Listed Sponsors
lead

Oncozyme Pharma Inc.

INDUSTRY